The European Medicines Verification Organisation (EMVO) has launched a newsletter, which informs about the statement from EMVO’s new President, the roles and responsibilities of the National Medicines Verification Organisations (NMVO) Observers, the experience from the Hungarian Medicines Verification Organisation in ending the stabilisation period, the Belgium's experience with the Nordic recommendations on the recalls of batches and withdrawal of products, as well as on the status of alerts in the European Medicines Verification System (EMVS).
The President of EMVO, Monika Derecque-Pois, has set the key priorities for the coming years and they are – to connect all end-users within EMVS, to establish trust between EMVO and the various EMVO stakeholders and NMVO communities, as well as to ensure the connection of partners and end-users to the Alert Management System.
On May 12, at the EMVO’s General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the NMVOs were approved. As one of the observers representing the group of small-scale countries (Slovakia, Norway, Croatia, Cyprus, Estonia, Iceland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta and Slovenia), will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane. The Polish Medicines Verification Organisation (KOWAL) and its General Manager Iwona McManus, representing the group of large-scale countries, as well as the Swedish Medicines Verification Organisation (e-VIS) and its General Manager Kristina von Sydow, representing the group of medium-scale countries, will work together with LZVO as NMVO Observers within EMVO’s Board.
In the newsletter, Peter Schneider, the General Manager of the Hungarian Medicines Verification Organization (HUMVO), talked about Hungary's experience in ending the stabilisation period, while Philippe Coene, the General Manager of the Belgian Medicines Verification Organization (BeMVO), shared his experience on the recommendations developed by the Nordic countries for recalling batches and withdrawing products within the EMVS.
Latest EMVS statistics shows that the number of monthly alert rate continues to decrease and reached its lowest point yet in April this year (0.14%), despite a peak at the end of April due to the incidents in Belgium and Poland, which generated over 88,000 alerts in one week.